Unknown
PHASE1, PHASE2
INTERVENTIONAL
NCT04702516
The Effect of Semaglutide on Bone Turnover in Patients With Increased Risk of Bone Fracture
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The hypothesis for this study is that the GLP-1Ra Semaglutide has a positive effect on the balance between build-up and degradation as well as the strength of the bones in men and women aged 40-85 years at increased risk of bone fractures. Treatment involves injection of Semaglutide 1.34 mg/ml once a week or corresponding volume of placebo once a week for 52 weeks. The effect will be measured by bone markers in blood samples, bone scans, bone tissue tests (bone biopsy), and direct bone strength measured by microindentation at the start and end of the study.
Interventions
Name:
Ozempic
Type:
DRUG
Description:
2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Name:
Placebo
Type:
DRUG
Description:
2 mg prefilled pen for subcutaneous injection, 0.25 mg for two weeks then 0.5 mg for two weeks and then 1 mg for another 48 weeks.
Primary Outcomes
Measure:
Procollagen type 1 N-terminal propeptide (P1NP)
TimeFrame:
Baseline and 52 weeks
Description:
Percentage changes in bone formation marker P1NP from baseline and after 12 months
Trial Information
NCT ID
NCT04702516
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE1, PHASE2
Sponsor
Morten Frost
Last Updated
December 15, 2025